Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year
Filters applied: . Clear all
Page 1
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators. EPILOG Investigators. N Engl J Med. 1997 Jun 12;336(24):1689-96. doi: 10.1056/NEJM199706123362401. N Engl J Med. 1997. PMID: 9182212 Free article. Clinical Trial.
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.
Kereiakes DJ, Lincoff AM, Anderson KM, Achenbach R, Patel K, Barnathan E, Califf RM, Topol EJ; EPIC Investigators; EPILOG investigators; EPISTENT investigators. Kereiakes DJ, et al. Am J Cardiol. 2002 Sep 15;90(6):628-30. doi: 10.1016/s0002-9149(02)02568-7. Am J Cardiol. 2002. PMID: 12231090 Clinical Trial. No abstract available.
Feedback